
Consumer Staples · Household Products
$104.16
+0.99%
Vol: 692K
Tuesday, June 16, 2026
No material news in the last 48 hours.
No material news in the last 48 hours.
No material news in the last 48 hours.
Annual Meeting May 14: all directors re-elected, Deloitte ratified, executive pay approved; independent chair proposal rejected. VP/Controller Andrew Scribner departing May 22; CFO Nelson Urdaneta takes interim principal accounting officer role. Declared $1.28/share quarterly dividend May 15. Building 1M sq ft manufacturing facility (~500 jobs). Kenvue acquisition synergies to integrate in 2H 2026. Huggies launched Natural Born Fighters campaign May 6. Stock $96.47 May 19; analysts reiterated Buy with $120 PT on May 11.
No material news in the last 48 hours.
No material news in the last 48 hours.
Kimberly-Clark held its 2026 Annual Meeting of Stockholders on May 14, 2026, where shareholders elected all nominated directors, ratified Deloitte & Touche LLP as auditor, and gave advisory approval to executive compensation. A shareholder proposal requiring an independent board chair was rejected. The board declared a regular quarterly dividend of $1.28 per share on the same day. The firm is set to integrate Kenvue's consumer health portfolio in the second half of 2026 following the $48.7 billion acquisition. Earlier in May, the company announced VP and Controller Andrew Scribner's departure effective May 22, 2026, with CFO Nelson Urdaneta temporarily assuming principal accounting officer duties. EPS projections for 2026 were lowered from $8.00 to $7.85, with 71% of analysts suggesting Hold. Shares opened May 18 at $97.43.
Kimberly-Clark announced May 1 that VP and Controller Andrew Scribner will depart effective May 22, 2026; CFO Nelson Urdaneta will temporarily assume principal accounting officer duties. Board declared a regular quarterly dividend of $1.28/share. Q1 2026 results exceeded expectations with 2.5% organic growth, 3% volume/mix growth, and revenue of $4.16B (vs $4.09B consensus). The pending $48.7B Kenvue acquisition received India CCI approval; closing anticipated 2H 2026 pending remaining regulatory clearance. Barclays maintained Equal-Weight and cut PT to $99 from $105. Consensus is Hold across 14 analysts with FY26 EPS estimates lowered to $7.85 from $8.00. New Kleenex Snap & Go format rolled out across US retailers. Risk: input cost pressures, 5.29% dividend sustainability questioned, integration execution on Kenvue.
Kimberly-Clark is holding its 2026 annual shareholder meeting on May 14. On May 1, the company announced VP and Controller Andrew Scribner will leave on May 22 to pursue other opportunities, with CFO Nelson Urdaneta temporarily taking on principal accounting officer duties. Scribner sold his remaining 4,095 shares on May 6, reducing his holdings to zero. Kimberly-Clark's Q1 2026 results topped expectations with 3% volume/mix growth, productivity gains, and continued preparation for the $48.7B Kenvue acquisition (shareholder-approved January 29, 2026) that will create a $32B global health and wellness leader. Huggies launched its "Natural Born Fighters" NICU campaign on May 6 with athletes Derick Hall and Allison Schmitt. Shares trading around $97.04 on May 14. 14 analysts rate Hold consensus.
Kimberly-Clark announced on May 1, 2026, that VP & Controller Andrew Scribner will leave the company effective May 22, 2026; CFO Nelson Urdaneta will temporarily assume principal accounting officer duties. Scribner sold 4,095 shares on May 6 for proceeds of $401,310. KMB shares fluctuated between $95.32 and $97.76 on May 12. The company is actively progressing its pending $48.7 billion acquisition of Kenvue, with leadership changes positioned as part of operational restructuring intended to enhance efficiency. Kimberly-Clark also announced it will present at the Barclays 18th Annual Americas Select Conference on May 6, 2026. Analyst consensus across 14 covering firms remains Hold (71% Hold, 14% Strong Buy, 7% Buy).
Kimberly-Clark announced a Controller departure and interim successor on May 5. On May 6, Controller Andrew Scribner sold 4,095 shares (~$401K). The $48.7B Kenvue acquisition is progressing, with the company having outlined a post-closing organizational structure and key leadership on April 15. Q1 2026 net sales were $4.2B (up 2.7%) with organic sales growth of 2.5%, reaffirming the FY26 outlook. Stock at ~$99.19 with reported intrinsic discount of 36.97%. Consensus is Hold with $113.29 average price target. Analysts cite input cost pressures and 5.29% dividend sustainability concerns.
Kimberly-Clark announced on May 1 that VP and Controller Andrew Scribner will leave the company effective May 22, 2026, with CFO Nelson Urdaneta temporarily assuming principal accounting officer duties for financial continuity. Scribner sold 4,095 shares at ~$98 for $401,310 on May 6. KMB will webcast its presentation at the Barclays 18th Annual Americas Select Conference on May 6. The company launched Huggies "Natural Born Fighters" NICU campaign on May 6 and Kleenex Snap & Go on May 4. KMB continues progressing toward its $48.7 billion acquisition of Kenvue. Shares traded $98.21-$100.10 on May 9, closing near $98.22 with a Hold consensus rating. 2026 price prediction is $113.29.
Kimberly-Clark reported Q1 2026 profit of $665M ($2.00/share) vs $567M ($1.70) YoY with 3% organic volume/mix growth. Stock price target raised to $106 at UBS from $105. Company is executing Powering Care transformation strategy and reducing tissue exposure while expanding into consumer health with Kenvue acquisition. Management cautioned about $150-170M additional cost impact from elevated oil prices.
Kimberly-Clark reported Q1 net sales up 2.7% with organic growth of 2.5%. However, EPS of $1.60 missed consensus of $1.93 by 17.1%. Gross margin improved but offset by cost pressures. Company warns of $150-170M additional input costs if oil remains near $100/barrel through H2. Kenvue acquisition expected H2 2026 closure. UBS raised PT to $106, analyst consensus 'Hold'.
| Company | Price | Day | 1M | Fwd P/E | Beta | Mkt Cap |
|---|---|---|---|---|---|---|
| CLCOLGATE | $90.83 | +0.28% | +0.7% | 22.4x | 0.32 | $72.5B |
| KMBKIMBERLY | $104.16 | +0.99% | +6.8% | 13.6x | 0.30 | $34.2B |
| CHDCHURCH | $98.53 | +0.21% | +1.6% | 24.0x | 0.47 | $23.3B |
| CLXCLOROX | $97.25 | +1.32% | +3.4% | 15.3x | 0.55 | $11.6B |
| WMTWALMART | $121.75 | +0.77% | -9.4% | 36.8x | 0.60 | $961.5B |
| COSTCOSTCO | $986.42 | +0.71% | -9.0% | 43.3x | 0.87 | $434.4B |
Price below 200d MA — bearish structure.